Literature DB >> 17253528

Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing.

D Blom1, M Ermers, L Bont, W M C van Aalderen, J B M van Woensel.   

Abstract

BACKGROUND: Acute bronchiolitis in infants and young children is associated with long-term airway disease also known as post-bronchiolitic wheezing. Two major hypotheses have been proposed to explain the association between bronchiolitis and PBW. The first hypothesis considers bronchiolitis to be the first manifestation of recurrent wheezing in infants and children who are susceptible to obstructive airway disease. The second hypothesis suggests that the infection and concomitant inflammatory reaction in the acute phase leads to airway epithelium injury resulting in long-term obstructive airway disease. In line with the latter hypothesis, corticosteroids may have a beneficial effect on the prevention of post-bronchiolitic wheezing.
OBJECTIVES: The objective of this review was to evaluate the effect of inhaled corticosteroids, started during the acute phase of bronchiolitis, on the prevention of post-bronchiolitic wheezing. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2006) which contains the Cochrane Acute Respiratory Infections Group's trials register, MEDLINE (1966 to September 2006), EMBASE (1980 to September 2006) and Current Contents (September 2006). Abstracts and reports of congresses (ERS 1999 to September 2005, ATS 1999 to September 2005) were obtained. We contacted experts in the field and pharmaceutical companies for ongoing or unpublished studies. SELECTION CRITERIA: Randomised placebo-controlled trials studying the effect of inhaled corticosteroids in children younger than two years of age with the clinical diagnosis of acute bronchiolitis were included. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and assessed trial quality using the Jadad 5-point scale. MAIN
RESULTS: Five studies matched the inclusion criteria, with a median Jadad score of 4 (Inter Quartile Range 3 to 4), involving 374 infants. Pooling of the data was limited, due to the clinical diversity of the studies. However, no effect of inhaled corticosteroids in the prevention of wheezing (diary records or GP diagnosed), hospital re-admissions or use of corticosteroids or bronchodilators could be demonstrated. Duration of therapy, length of follow up or causative agent (respiratory syncytial virus or not) did not influence the pooled effect. In the three studies that also evaluated the adverse events, none were reported. AUTHORS'
CONCLUSIONS: This review does not demonstrate an effect of inhaled corticosteroids given during the acute phase of bronchiolitis in the prevention of post-bronchiolitic wheezing. The small number of included participants and the inability to pool all clinical outcomes precludes us from making strong recommendations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253528     DOI: 10.1002/14651858.CD004881.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  18 in total

Review 1.  Animal models of human respiratory syncytial virus disease.

Authors:  Reinout A Bem; Joseph B Domachowske; Helene F Rosenberg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

2.  Respiratory syncytial virus: diagnosis, treatment and prevention.

Authors:  Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

3.  Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.

Authors:  Avraham Beigelman; Megan Isaacson-Schmid; Geneline Sajol; Jack Baty; Oscar M Rodriguez; Erin Leege; Kevin Lyons; Toni L Schweiger; Jie Zheng; Kenneth B Schechtman; Mario Castro; Leonard B Bacharier
Journal:  J Allergy Clin Immunol       Date:  2014-11-18       Impact factor: 10.793

4.  Prospective multicenter study of bronchiolitis: predictors of an unscheduled visit after discharge from the emergency department.

Authors:  Agatha Norwood; Jonathan M Mansbach; Sunday Clark; Muhammad Waseem; Carlos A Camargo
Journal:  Acad Emerg Med       Date:  2010-04       Impact factor: 3.451

5.  A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants.

Authors:  Michaël V Lukens; Alma C van de Pol; Frank E J Coenjaerts; Nicolaas J G Jansen; Vera M Kamp; Jan L L Kimpen; John W A Rossen; Laurien H Ulfman; Carline E A Tacke; Marco C Viveen; Leo Koenderman; Tom F W Wolfs; Grada M van Bleek
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

6.  What drives prescribing of asthma medication to children? A multilevel population-based study.

Authors:  Mira G P Zuidgeest; Liset van Dijk; Peter Spreeuwenberg; Henriëtte A Smit; Bert Brunekreef; Hubertus G M Arets; Madelon Bracke; Hubert G M Leufkens
Journal:  Ann Fam Med       Date:  2009 Jan-Feb       Impact factor: 5.166

7.  Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005).

Authors:  T M Berger; C Aebi; A Duppenthaler; M Stocker
Journal:  Infection       Date:  2008-12-09       Impact factor: 3.553

Review 8.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

9.  The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial.

Authors:  Marieke J J Ermers; Maroeska M Rovers; Job B van Woensel; Jan L L Kimpen; Louis J Bont
Journal:  BMJ       Date:  2009-03-31

10.  Pharmacological management of acute bronchiolitis.

Authors:  Melvin Wright; Charles J Mullett; Giovanni Piedimonte
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.